TICKERNERD
Menu
ERASERASHealthcare · Biotechnology

ERAS Stock Forecast: Erasca, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$18
−1.71% on the day

The 10 Wall Street analysts covering Erasca, Inc. hold a median 12-month price target of $23 — +26.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$6.3B
Ticker Nerd rank
66 / 100
Median analyst target
$23
Analysts covering
10
Total return, dividends reinvested
1W
−5.5%
1M
−3.4%
YTD
+379.6%
1Y
+1183.5%
From 52W high
−20.6%
From 52W low
+1174.3%
$1
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ERAS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Erasca, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
93
Momentum
88
Accruals
81
Quality
69
Issuance
50
Revisions
48
Growth
33
Volatility
27
Size
21

Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (27): The share price moves around a lot.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Erasca, Inc. — and when they’d sell — is the membership.

Wall Street

ERAS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ERAS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Oct 25Jan 26Apr 26Jul 26ERASHigh $30Median $23Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $18Median $23High $30

The green dot is the last close — the median target sits +26.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 July 2026Morgan StanleyMaintainsEqual-Weight$12 → $21
20 July 2026Morgan StanleyMaintainsEqual-Weight—
14 July 2026B of A SecuritiesMaintainsNeutral$16 → $18
14 July 2026B of A SecuritiesMaintainsNeutral—
4 June 2026B of A SecuritiesUpgradeNeutral$9.00 → $16
4 June 2026B of A SecuritiesUpgradeNeutral—
12 May 2026MizuhoMaintainsOutperform—
27 Apr 2026StifelMaintainsBuy—
18 Mar 2026JP MorganMaintainsOverweight—
16 Mar 2026GuggenheimMaintainsBuy—
13 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026Piper SandlerMaintainsOverweight—
6 Mar 2026Clear StreetMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
16 Jan 2026Piper SandlerMaintainsOverweight—
13 Jan 2026HC Wainwright & Co.MaintainsBuy—
7 Jan 2026Piper SandlerInitiatesOverweight—
9 Dec 2025MizuhoMaintainsOutperform—
14 Nov 2025GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ERAS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
7
Fundamentals

Erasca, Inc. (ERAS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−40.4×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
13.8×

Cheaper than 7% of US stocks

EV / EBITDA
−41.7×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−69.9%

Higher than 17% of US stocks

Return on assets
−17.9%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ERAS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ERASErasca, Inc.$6.3B
66
CGONCG Oncology, Inc.$6.3B
22
MIRMMirum Pharmaceuticals, Inc.$6.3B
73
XENEXenon Pharmaceuticals, Inc.$6.0B
43
RYTMRhythm Pharmaceuticals, Inc.$6.6B
82
DNTHDianthus Therapeutics, Inc.$5.8B
53
COGTCogent Biosciences, Inc.$6.7B
41
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ERAS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ERAS news & analysis

Erasca, Inc. Deadline: ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit

PRNewsWire · 4 Aug 2026negative

Rosen Law Firm reminded purchasers of Erasca, Inc. common stock that the lead plaintiff deadline in a securities fraud lawsuit is August 10, 2026. The class period covers purchases made between January 14, 2025 and April 26, 2026, inclusive.

Why it matters — ERAS watchers may care because investors who bought during the class period may be entitled to compensation through a contingency fee arrangement in the securities fraud case.

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

GlobeNewsWire · 3 Aug 2026negative

Bragar Eagel & Squire, P.C. reminded Erasca, Inc. (ERAS) investors of an August 10 lead plaintiff deadline, urging those who suffered large losses to contact the firm to discuss their rights.

Why it matters — An ERAS watcher would care because the notice points to investor losses tied to the company and an ongoing securities-related legal process.

Kaplan Fox Notifies Erasca, Inc. (ERAS) Investors of an Upcoming Lead Plaintiff Deadline on August 10, 2026

Newsfile Corp · 3 Aug 2026negative

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. on behalf of investors who purchased or acquired Erasca securities between January 14, 2025 and April 26, 2026. A lead plaintiff deadline is set for August 10, 2026.

Why it matters — ERAS watchers should be aware of the class action lawsuit and upcoming lead plaintiff deadline, as it introduces legal and financial uncertainty for the company.

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law

PRNewsWire · 3 Aug 2026negative

Shareholder rights law firm Schall, Brown & Schwartz LLP reminded investors of a securities fraud class action lawsuit against Erasca, Inc., alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The firm invited shareholders who purchased ERAS shares during the class period to contact it regarding possible lead plaintiff appointments.

Why it matters — ERAS watchers would care because the company faces a securities fraud class action lawsuit alleging violations of U.S. securities laws.

Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS

PRNewsWire · 3 Aug 2026negative

The DJS Law Group is reminding investors about a class action lawsuit filed against Erasca, Inc. (ERAS) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Shareholders who bought ERAS shares during the specified class period are encouraged to contact the firm regarding possible lead plaintiff appointments.

Why it matters — A securities class action alleging violations against Erasca could carry legal, financial, and reputational implications for the company and its shareholders.

FAQ

Frequently asked questions about ERAS stock

What is the ERAS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Erasca, Inc. have a median 12-month price target of $23, with estimates ranging from $18 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ERAS stock a buy right now?

Of the 10 analysts covering Erasca, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Erasca, Inc. 66 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ERAS?

As at 1 Aug 2026, Erasca, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).

Will ERAS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +26.1% from the last close, and Ticker Nerd's factor model ranks Erasca, Inc. 66 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ERAS stock forecast for 2030?

No analyst covering Erasca, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERAS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $30 over the next 12 months.

How has ERAS stock performed over the past year?

Erasca, Inc. returned +1183.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Erasca, Inc. do?

Erasca, Inc. is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway.

What is the latest news on ERAS?

The most recent item we track (PRNewsWire, 4 Aug 2026): "Erasca, Inc. Deadline: ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit". Rosen Law Firm reminded purchasers of Erasca, Inc. common stock that the lead plaintiff deadline in a securities fraud lawsuit is August 10, 2026. The class period covers purchases made between January 14, 2025 and April 26, 2026, inclusive.

Company

About Erasca, Inc.

Erasca, Inc. is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway. Operating today in the biotechnology and oncology drug development industry, the company concentrates on targeted small-molecule and biologic programs for biomarker-selected patient populations, particularly those with RAS- and MAPK-driven solid tumors. Erasca’s current pipeline includes candidates such as naporafenib, a pan-RAF inhibitor in late-stage clinical evaluation for NRAS-mutated melanoma and other RAS/MAPK tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor that together form a combination strategy to inhibit multiple nodes in the pathway. Additional programs target RAS directly and address resistance mechanisms via approaches like pan-RAS and pan-KRAS inhibitors and EGFR-directed agents. Founded in 2018 and headquartered in San Diego, California, Erasca plays a specialized role in the healthcare market as a developer of precision oncology assets rather than commercialized drugs, collaborating with academic centers and partners to advance its clinical trials.

CEO Dr. Jonathan E. Lim M.D. · 103 employees · United States · https://www.erasca.com